The Annual General Meeting of sanofi-aventis shareholders was held on May 31, 2005. The General Meeting approved the financial statements for the year ended December 31,2004. Also approved was the distribution of a net dividend of 1.20 euro per share, a 17.6% increase over the previous year. The dividend will be paid out on June 7, 2005. The General Meeting has reappointed PricewaterhouseCoope
Paris, Frankrike & Genève, Schweiz 23 maj 2005 - World Heart Federation och sanofi-aventis tillkännagav idag att de har ingått ett treårigt partnerskapsavtal för att med förenade krafter förbättra förebyggandet och kontrollen av hjärtkärlsjukdomar. Tillkännagivandet gjordes vid World Heart Federations sjätte internationella kongress om förebyggande kardiologi (ICPC) i Brasilien, och bekräf
Major data presented at ASCO 2005 on Eloxatin® in combination with other chemotherapeutic drugs and with new targeted agents Paris, France May 18, 2005 - Sanofi-aventis announced today the results of key trials on the anti-cancer drug Eloxatin® (oxaliplatin for injection), presented at the 2005 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Orlando, Florida. The study f
Contact : Anne Bancillon 33-6-86-31-03-89 ~ Taxotere®-Based Chemotherapy Reduces Risk of Death by 23 Percent ~ Final results from the largest international study in the reatment of advanced stomach cancer, also known as gastric cancer, demonstrated that patients who received a Taxotere® (docetaxel) Injection Concentrate-based chemotherapy regimen (Taxotere®, cisplatin and 5-fluorouracil)
market growth1 at 11.9%2 on a comparable basis Strong growth in adjusted EPS3: up 27.7%2 at 1.06 euros per share Sanofi-aventis on track to meet 2005 guidance The consolidated statement of income of sanofi-aventis for the first quarter of 2005, presented in Appendix 4, shows net income of 531 million euros and is impacted by the accounting treatment of the combination with Aventis and by re
Press release from Professor Luc Van Gaal (University Hospital Antwerp), principal investigator of the Rio-Europe trial, entitled: 1st year results of RIO-EUROPE study published in the Lancet. Best regards, Media Relations Department 174, avenue de France - 75013 PARIS - FRANCE - Tél. : +33 1.53.77.40.00 - Fax : +33 1.53.77.41.33 - www.sanofi-aventis.com Sanofi-aventis - Siège Social :
Contact : Dr. Robert SEBBAG +33 (0)1 53 77 47 80 +33 (0)6 08 17 21 83 EMBARGO UNTIL APRIL 15, 2005 1:00 p.m. (CET) In his address to the closing plenary session of BioVision the World Life Sciences Forum - Jean-François Dehecq, Chairman and CEO of sanofi-aventis, set out the guiding principles of his Group's strategy in its Policy of Access to Medicines in the "Southern Countries".
FDA ISSUES APPROVABLE LETTER FOR AMBIEN CR (ZOLPIDEM TARTRATE EXTENDED RELEASE) CIV FOR THE TREATMENT OF INSOMNIA Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that it has received an approvable letter from the U.S. Food and Drug Administration (FDA) for AMBIEN CR (zolpidem tartrate extended release) CIV. AMBIEN CR is the controlled-release formulation of zolpidem, the worlds
Major U.S. public health initiative complements sanofi pasteurs leadership in global pandemic preparedness Sanofi pasteur, the vaccines business of the sanofi-aventis Group, has been awarded a $97 million contract from the U.S. Health and Human Services Department (HHS) to speed the production process for new cell culture influenza vaccines in the U.S. and the design of a U.S.-based cell-cultu
Sanofi-aventis announced today the simultaneous signature of a medium-term syndicated credit agreement amounting to 8 billion and four bilateral credit facilities amounting to 500 million each. The syndicated credit agreement consists of two revolving credit lines each having a different maturity: a 5.5 billion five-year tranche with the possibility of extending the maturity up to seven
Today sanofi-aventis announced that, at the request of sanofi-aventis, Apotex, and their respective affiliates, the U.S. District Court for the Southern District of New York has approved an extension of the date for submission by the parties of the pre-trial order in its Plavix® patent-infringement litigation with Apotex and Dr. Reddys Laboratories. The new date is May 13, 2005. The submission
in partnership with the Nelson Mandela Foundation and the South African Department of Health THE TB FREE PROGRAM for the treatment of tuberculosis sufferers In Johannesburg today, South African Health Minister Dr. Manto Tshabalala-Msimang and sanofi-aventis Chairman and CEO Jean-François Dehecq inaugurated the first training center in support for patients receiving treatment for tuberculosi
